HPC
MCRB icon

HM Payson & Co’s Seres Therapeutics MCRB Stock Holding History

HM Payson & Co’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39
Closed -$16K – 1134
2021
Q1 		$16K Hold
39
– – ﹤0.01% 808
2020
Q4 		$19K Sell
39
-10
-20% -$5.86K ﹤0.01% 777
2020
Q3 		$28K Buy
+49
New +$16.3K ﹤0.01% 674

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

HM Payson & Co's MCRB Position: Q2 2021 in Review

HM Payson & Co sold out of Seres Therapeutics (MCRB) in Q2 2021, closing a stake of 39 shares — an estimated $16K sold.

HM Payson & Co first reported a position in MCRB in Q3 2020 and held it in 3 quarters. The position peaked at $28K in Q3 2020. 146 funds tracked by Wall St. Rank hold MCRB as of Q2 2021.

  • HM Payson & Co reported no remaining Seres Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HM Payson & Co sold 39 Seres Therapeutics shares in Q2 2021, an estimated $16K.
  • HM Payson & Co first reported a position in Seres Therapeutics in Q3 2020 and held it in 3 quarters.
  • HM Payson & Co's Seres Therapeutics position peaked at $28K in Q3 2020.
  • 146 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2021.

Based on HM Payson & Co's 13F filing for Q2 2021, filed 17 Aug 2021.